Variability of residual platelet function despite clopidogrel treatment in patients with peripheral arterial occlusive disease


      Residual platelet function despite treatment with clopidogrel may predict an unfavourable cardiovascular outcome. The majority of studies have investigated the effects of clopidogrel administration in conjunction with aspirin in patients undergoing percutaneous coronary intervention. The primary objective of the present study was to assess the platelet response to clopidogrel in the absence of aspirin in patients with peripheral arterial occlusive disease (PAOD) and to investigate whether non-responsiveness to clopidogrel is reproducible during long-term follow-up. Fifty-four clinically stable PAOD patients on a maintenance dose of 75 mg/d clopidogrel were enrolled in this study. Platelet function was assessed at baseline and after a median follow-up of 18 months using light transmittance aggregometry (LTA) with 2 μM ADP as an agonist. HPLC-coupled mass spectrometry was used to detect clopidogrel and clopidogrel carboxylic acid, the main metabolite of clopidogrel. Residual platelet function, as defined by late aggregation values within the reference range (i.e., >43%), was observed in 35.2% of patients at baseline and 17.6% during follow-up. During the observation period, 26.5% had switched from responder to non-responder status or vice versa. Among non-responders, either clopidogrel or its metabolite was detected in 89.5% and 83.3% of patients at baseline and at follow-up, respectively. We conclude that non-responsiveness to clopidogrel as determined by ADP-induced LTA is not stable over time. This phenomenon cannot be attributed to non-compliance alone.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • CAPRIE Steering Committee
        A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).
        Lancet. 1996; 348: 1329-1339
        • Yusuf S.
        • Zhao F.
        • Mehta S.R.
        • et al.
        Clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
        N Engl J Med. 2001; 345: 494-502
        • Steinhubl S.R.
        • Berger P.B.
        • Mann J.T.
        • et al.
        CREDO Investigators. Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
        J Am Med Assoc. 2002; 288: 2411-2420
        • Gachet C.
        Regulation of platelet functions by P2 receptors.
        Annu Rev Pharmacol Toxicol. 2006; 46: 277-300
        • Savi P.
        • Herbert J.M.
        Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis.
        Semin Thromb Hemost. 2005; 31: 174-183
        • Gurbel P.A.
        • Tantry U.S.
        Clopidogrel resistance?.
        Thromb Res. 2007; 120: 311-321
        • Norgren L.
        • Hiatt W.R.
        • Dormandy J.A.
        • et al.
        Inter-society consensus for the management of peripheral arterial disease (TASC II).
        Eur J Vasc Endovasc Surg. 2007; 33: S1-S75
        • Linnemann B.
        • Schwonberg J.
        • Mani H.
        • Prochnow S.
        • Lindhoff-Last E.
        Standardization of light transmittance aggregometry for monitoring antiplatelet therapy: an adjustment for platelet count is not necessary.
        J Thromb Haemost. 2008; 6: 677-683
        • Mani H.
        • Toennes S.W.
        • Linnemann B.
        • et al.
        Determination of clopidogrel main metabolite in plasma: a useful tool for monitoring therapy?.
        Ther Drug Monit. 2008; 30: 84-89
        • Lainesse A.
        • Ozalp Y.
        • Wong H.
        • Alpan R.S.
        Bioequivalence study of clopidogrel bisulfate film-coated tablets.
        Arzneimittelforschung. 2004; 54: 600-604
        • McEwen J.
        • Strauch G.
        • Perles P.
        • et al.
        Clopidogrel bioavailability: absence of influence of food or antacids.
        Semin Thromb Hemost. 1999; 25: 47-50
        • Gachet C.
        P2 receptors, platelet function and pharmacological implications.
        Thromb Haemost. 2008; 99: 466-472
        • Matetzky S.
        • Shenkman B.
        • Guetta V.
        • et al.
        Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
        Circulation. 2004; 109: 3171-3175
        • Serebruany V.L.
        • Steinhubl S.R.
        • Berger P.B.
        • et al.
        Variability in platelet responsiveness to clopidogrel among 544 individuals.
        J Am Coll Cardiol. 2005; 45: 246-251
        • Cassar K.
        • Bachoo P.
        • Ford I.
        • Greaves M.
        • Brittenden J.
        Variability in responsiveness to clopidogrel in patients with intermittend claudication.
        Eur J Vasc Endovasc Surg. 2006; 32: 71-75
        • Ziegler S.
        • Maca T.
        • Alt E.
        • et al.
        Monitoring of antiplatelet therapy with the PFA-100® in peripheral angioplasty patients.
        Platelets. 2002; 13: 493-497
        • Pidcock M.
        • Harrison P.
        Can the PFA-100® be modified to detect P2Y12 inhibition?.
        J Thromb Haemost. 2006; 4: 1424-1426
        • Gurbel P.A.
        • BLiden K.P.
        • Hiatt B.L.
        • O’Connor C.M.
        Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pre-treatment platelet reactivity.
        Circulation. 2003; 107: 2908-2913
        • Gurbel P.A.
        • Bliden K.P.
        Durability of platelet inhibition by clopidogrel.
        Am J Cardiol. 2003; 91: 1123-1125
        • Harrison P.
        • Segal H.
        • Silver L.
        • et al.
        Lack of reproducibility of assessment of aspirin responsiveness by optical aggregometry and two platelet function tests.
        Platelets. 2008; 19: 119-124
        • Schwartz K.A.
        • Schwartz D.E.
        • Ghosheh K.
        • et al.
        Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction.
        Am J Cardiol. 2005; 95: 973-975
        • Cotter G.
        • Shemesh E.
        • Zehavi M.
        • et al.
        Lack of aspirin effect: aspirin resistance or resistance to taking aspirin?.
        Am Heart J. 2004; 147: 293-300
        • Siller-Matula J.
        • Schroer K.
        • Wojta J.
        • Huber K.
        Thienopyridines in cardiovascular disease: focus on clopidogrel resistance.
        Thromb Haemost. 2007; 97: 385-393
        • Siller-Matula J.M.
        • Lang I.
        • Christ G.
        • Jilma B.
        Calcium-channel blockers reduce the antiplatelet effect of clopidogrel.
        J Am Coll Cardiol. 2008; 52: 1557-1563
        • Gilard M.
        • Arnaud B.
        • Cornily J.C.
        • et al.
        Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.
        J Am Coll Cardiol. 2008; 51: 256-260
        • Hochholzer W.
        • Trenk D.
        • Bestehorn H.P.
        • et al.
        Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement.
        J Am Coll Cardiol. 2006; 48: 1742-1750
        • Buonamici P.
        • Marcucci R.
        • Migliorini A.
        • et al.
        Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis.
        J Am Coll Cardiol. 2007; 49: 2312-2317
        • Frere C.
        • Cuisset T.
        • Quilici J.
        • et al.
        ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome.
        Thromb Haemost. 2007; 98: 838-843
        • Marcucci R.
        • Paniccia R.
        • Antonucci E.
        • et al.
        Residual platelet reactivity is an independent predictor of myocardial injury in acute myocardial infarction patients on antiaggregant therapy.
        Thromb Haemost. 2007; 98: 844-851
        • Samara W.M.
        • Bliden K.P.
        • Tantry U.S.
        • Gurbel P.A.
        The difference between clopidogrel responsiveness and post-treatment platelet reactivity.
        Thromb Res. 2005; 115: 89-94
        • Michelson A.D.
        • Linden M.D.
        • Furman M.I.
        • et al.
        Evidence that pre-existent variability in platelet response to ADP accounts for clopidogrel resistance.
        J Thromb Haemost. 2007; 5: 75-81
        • Aleil B.
        • Ravanat C.
        • Cazenave J.P.
        • et al.
        Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases.
        J Thromb Haemost. 2005; 3: 85-92
        • Geiger J.
        • Teichmann L.
        • Grossmann R.
        • et al.
        Monitoring of clopidogrel action: comparison of methods.
        Clin Chem. 2005; 51: 957-965
        • Gurbel P.A.
        • Bliden K.P.
        • Samara W.
        • et al.
        Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results from the CREST study.
        J Am Coll Cardiol. 2005; 46: 1827-1832
        • Barragan P.
        • Bouvier J.L.
        • Roquebert P.O.
        • et al.
        Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphorylation.
        Catheter Cardiovasc Interv. 2003; 59: 295-302
        • Angiolillo D.J.
        • Alfonso F.
        Platelet function testing and cardiovascular outcomes: steps forward in identifying the best predictive measure.
        Thromb Haemost. 2007; 98: 707-709